We offer a variety of preclinical efficacy, POC and MOA studies in different animal models of both type I and type II diabetes. We have an excellent track record when it comes to working with difficult models like ZDF rats and db/db mice and have extensive knowledge of how to quantitate beta-cell mass and other histological-pathological endpoints of diabetes.
- Highly experienced with the majority of commercially available models (C57/BL6, ob/ob, db/db mice, and SPD rats, ZDF rats)
- Oral/intravenous/intraperitoneal glucose tolerance tests (OGTT, IVGTT, IPGTT) and insulin tolerance tests
- Continuous (24h) glucose monitoring in rats
- Insulin sensitivity (endogenous glucose production and tissue glucose uptake) using the hyperinsulinaemic euglycaemic clamp
- NOD mice and pancreatectomy
- NASH models
OGTT in rats and mice
OGTT glucose - lean SPD rats
OGTT glucose - Gubra DIO rats
Acute OGTT in C57BI6/J mice
AUC OGTT in C57BI6/J mice
Chronic efficacy studies
- Longterm effects on glucose homeostasis in ZDF rats
- Chronic (7 days to 12+ weeks) efficacy testing
- Experienced with most available 1000 models from db/db and NOD mice to ZDF and ZSF1 rats
- In-house developed and validated Glucose Compound pancreatectomy model
- Blood chemistry (insulin, HbA1c, glucose, GLP-1, PYY etc)
Longterm effects on glucose homeostasis in ZDF rats
Data demonstrating the efficacy of 8 weeks chronic treatment with the DPP-4i (linagliptin), SGLT-2i (dapagliflozin), GLP-1 (liraglutide) and SUR (glibenclamide) on OGTT insulin and glucose levels in male ZDF rats. See paper: Hansen HH et al, 2014.
Longterm effects on pancreatic markers
Gubra has characterized the longterm effect of GLP-1 analogs on blood glucose, beta cell mass and signs of pancreatitis. See paper: Vrang et al, 2012. Gubra is highly experienced with the assessments of beta cell dynamics in ZDF rats and db/db mice. These data are pivotal when assessing a direct or indirect effect of a given compound”:
Mode of Action studies
- Hyperinsulinaemic euglycaemic clamp studies
- Gastric Bypass surgery
Hyperinsulinaemic euglycaemic clamp
Glucose infusion rate during hyperinsulinaemic euglycaemic clamp in lean and male Gubra DIO rats. Data demonstrates a reduced insulin sensivity in Gubra DIO rats compared to lean animals, and improved insulin sensitivity following treatment with the thiazolidinedione Pioglitazone.
Glucose infusion rate
The male ZDF rat model
Thorough knowledge of the ZDF rat model is a must if you want to optimize your study design in accordance with drug type and mode of action. Take a look at our film on the subject to learn more about how this model can be used.
However, if you're looking to evaluate the potential proliferative effects of various interventions (pharmacological or non-pharmacological), our research has shown that the db/db mouse model is preferable. To learn more about how the db/db model can be used, see our paper on the subject.
of science Read
We know our results ultimately have to generate value for your company. That’s why we focus on the quality and completeness of the data we provide. We choose the methodology that will yield the most usable results for your company. Scientific research requires care, accuracy and precision. This is the delicate balance we walk. Pursuing methods with scientific merit to give you results that you can use, and that will ultimately generate value for your business.
At Gubra, we are committed to high quality deliverables. Through the strength of our quality systems and processes, from administration and study conduction to data management and reporting, we provide structured, professional and experienced services. All critical processes are governed by Standard Operating Procedures that along with quality control documentation are controlled by our Quality Assurance Group. Consistent training and evaluation processes throughout the organization ensure Gubras dynamic and evolving Quality Assurance System.
keep it simple Read
Just because it’s science, doesn’t mean the research has to be complicated. One of our mantras is the need to get clear, simple answers from research. It’s true, with limited time and resources and infinite pressure to produce results, it can be very tempting to get the most bang for your proverbial buck by trying to include as many endpoints in a study as possible. Yet, what often happens with this approach is that you get inconclusive results that require further investigation, taking more time and using more resources. By taking a straightforward approach to study design, we ensure our customers get clear answers they can use.